Informal Request for ATI Records Previously Released

Organization: Health Canada

Year: 2024

Month: June

Request Number: A-2023-001271

Request Summary: New Drug Submission (NDS) for avapritinib filed by Blueprint Medicines Corporation was accepted into review by Health Canada in or around November 2023. Provide the Product Information Template: Regulatory Enrollment Process (the equivalent of Section #67 of the previous HC/SC-3011 Drug Submission Application Form) for the Avapritinib NDS, setting out the proposed indication/use of the new drug.

Disposition: Disclosed in part

Number of pages: 11

Date modified: